Who are SIBP-01's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EngerixB, GlaxoSmithKline Vaccines, EngerixTM-B, Engerix B, Hepatitis B recombinant vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, RECOMBIVAX HB™.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sibp-01.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

SIBP-01 — Competitive Intelligence Brief

SIBP-01 (SIBP-01) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant vaccine Hepatitis B surface antigen (HBsAg) Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

SIBP-01 (SIBP-01) — Shanghai Institute Of Biological Products. SIBP-01 is a recombinant hepatitis B vaccine candidate designed to provide immunological protection against hepatitis B virus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SIBP-01 TARGET	SIBP-01	Shanghai Institute Of Biological Products	phase 3	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
EngerixB, GlaxoSmithKline Vaccines	EngerixB, GlaxoSmithKline Vaccines	University of British Columbia	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
EngerixTM-B	EngerixTM-B	GlaxoSmithKline	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Engerix B	Engerix B	Crucell Holland BV	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Hepatitis B recombinant vaccine	Hepatitis B recombinant vaccine	Pontificia Universidad Catolica de Chile	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Recombinant Human Papillomavirus Nonavalent Vaccine	Recombinant Human Papillomavirus Nonavalent Vaccine	National Cancer Institute (NCI)	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
RECOMBIVAX HB™	RECOMBIVAX HB™	Merck Sharp & Dohme LLC	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant vaccine class)

GlaxoSmithKline · 5 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Crucell Holland BV · 2 drugs in this class
Shanghai Institute Of Biological Products · 2 drugs in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
University of British Columbia · 1 drug in this class
Fundacion SEIMC-GESIDA · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SIBP-01 — Competitive Intelligence Brief. https://druglandscape.com/ci/sibp-01. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab